- Monash University and ClinChoice Inc. have formed a strategic partnership to accelerate early-phase clinical trials and support development of innovative therapies.
- The collaboration combines Monash’s clinical trial network and research capabilities with ClinChoice’s global CRO expertise in development, regulatory, and data science.
ClinChoice Inc. and Monash University have entered into a strategic partnership aimed at accelerating early-phase clinical development and advancing innovative therapies toward patients. The collaboration brings together the university’s research and clinical trial infrastructure with the CRO’s global development, regulatory, and data science capabilities.
The agreement focuses on improving the speed and execution of early-stage clinical trials across Australia and international research settings. Monash contributes access to one of Australia’s largest clinical trial networks, including affiliated health services, general practitioners, and a patient population of approximately 4.5 million people.
ClinChoice, a global CRO with operations across more than 15 countries, will support the partnership through its experience in clinical development and therapeutic expertise across multiple disease areas. The collaboration is intended to enable more coordinated and patient-centric research programs.
The companies said the partnership is designed to address growing demand for faster clinical development timelines by combining academic research capabilities with commercial clinical execution. The initiative will focus particularly on early-phase studies, where speed and data quality are critical to advancing drug candidates.
“This collaboration is a strong testament to ClinChoice’s mission to support innovation through academic and clinical partnerships.”
Kevin Xu, Chairman and CEO of ClinChoice
Sign up to the free weekly newsletter for all the latest news, resources and podcasts in contract manufacturing. 
